Clinical Pharmacokinetics in Monitoring Chronic Medication with Anti-Epileptic Drugs

  • E. van der Kleijn
  • P. J. M. Guelen
  • C. van Wijk
  • I. Baars


Recognition that one acute dosage or regimen of dosages of anti-epileptic drugs can seldom predict a desired intensity, onset and/or duration of the therapeutic effect together with the progress in the analytical procedures to determine these drugs in body fluids have strongly stimulated the development of clinical pharmacokinetics. The availability of drug concentrations in body fluids has improved the possibility of monitoring patients on chronic medication. Clearance data calculated on collections of parameters (concentrations, dosage-interval and body weight or body surface) have opened the possibility to establish individual dosage regimens for a single drug or combination of drugs. To cure a disease, suppress (abnormal) physiological functions or support biochemical processes of an individual, a certain amount of one drug or a combination of drugs in the body will be required. The concentration reached in the biological environment where the pharmacological activity is thought to be located as well as in other areas of the body will depend on the regional physiological and physico-chemical characteristics of organs, tissues and their constituent elements. Flow of body fluids largely controls dispersion of drugs through the body. Diffusion controls the distribution of drugs in inadequately perfused body regions. Binding, generally considered an extremely rapid process, will largely control the ultimate regional, cellular and subcellular differences in concentration. The higher the affinity for extravascular, extra- or intracellular body constituents the lower the plasma concentration.


Clinical Pharmacokinetic Squirrel Monkey Chronic Medication White Matter Structure Reciprocal Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ashley, J. J., Levy, G.: Kinetics of diphenylhydantoin elimination in rat. J. Pharmacokinetics and Biopharmaceutics 1, 99 (1973).CrossRefGoogle Scholar
  2. 2.
    Atkinson, A. J., Shaw, J. M.: Pharmacokinetic study of a patient with diphenylhydantoin toxicity. Clin. Pharmacol. Therap. 14, 521 (1973).Google Scholar
  3. 3.
    Augsberger, A.: Alte und neue Faustregeln für die Arzneidosierung bei Kindern. Triangel 5, 200 (Sandoz AG Nürnberg, 1962).Google Scholar
  4. 4.
    Blackwell, B.: Patient Compliance. New Engl. J. Med. 1973, 249.Google Scholar
  5. 5.
    Bochner, F., Hooper, W. D., Tyrer, J. H., Eadie, M. J.: Effect of dosage increments on blood phenytoin concentrations. J. Neurol. Neurosurg. Psychiat. 35, 873 (1972).PubMedCrossRefGoogle Scholar
  6. 6.
    Buchanan, R. A., Fernandez, L., Kinkel, A. W.: Absorption and elimination of ethosuximide in children. J. clin. Pharmacol. 9, 393 (1969).Google Scholar
  7. 7.
    Buchthal, F., Lennox-Buchthal, M. A.: Phenobarbital: Relation of serum concentration to control of seizures. In: Anti-epileptic Drugs (Eds. D. M. Woodbury, J. K. Penry, R. P. Schmidt) 335. New York: Raven Press 1973.Google Scholar
  8. 8.
    Chang, Tsun, Glazko, A. J.: Diphenylhydantoin, Biotransformation. In: Anti-epileptic Drugs (Eds. D. M. Woodbury, J. K. Penry, R. P. Schmidt) 149. New York: Raven Press 1973.Google Scholar
  9. 9.
    Unit Dose Blister Packaging Machine. Amer. J. of Hosp. Pharm. April 1974.Google Scholar
  10. 10.
    Christiansen, J.: Assay of carbamazepine and metabolites in plasma by quantitative thin layer chromatography. In: Methods of analysis of anti-epileptic drugs (Eds. J. W. A. Meijer, H. Meinardi, C. Gardner-Thorpe, E. van der Kleijn), ICS 286, 187, Amsterdam: Excerpta Medica, New York: American Elsevier Co., Inc. 1973.Google Scholar
  11. 11.
    Dyton, P. G., Perel, J. M.: Physiological and Physicochemical Bases of drug interactions in man. Ann. N. Y. Acad. Sci. 179, 67 (1971).CrossRefGoogle Scholar
  12. 12.
    Dijkhuis, J. C., Ferguson, G. E. T.: Drooggevroren standaard serum en plasma voor antiepileptica bepalingen. Pharm. Weekbl. 109, 48 (1974).Google Scholar
  13. 13.
    Dijkhuis, I. C., Vervloet, E.: Rapid determination of the anti-epileptic drug di-n-propylacetic acid in serum. Pharm. Weekbl. 109, 42 (1974).Google Scholar
  14. 14.
    Glazko, A. J., Chang Tsun: Diphenylhydantoin: Absorption, distribution and excretion. In: Anti-epileptic Drugs (Eds. D. M. Woodbury, J. K. Penry, R. P. Schmidt) 127. New York: Raven Press 1973.Google Scholar
  15. 15.
    Dill, W. A., Peterson, L., Chang, T., Glazko, A. J.: Physiological disposition of methylethyl suximide in animals and man. Abstracts of Papers 149th Meeting ACS Detroit 1965, 30N.Google Scholar
  16. 16.
    Firemark, H., Barlow, C. F., Roth, L. J.: The entry accumulation and binding of diphenylhydantoin-2-14C in brain. Int. J. Neuropharmacol. 2, 25 (1963).CrossRefGoogle Scholar
  17. 17.
    Glazko, A. J., Chang, T., Baukema, J., Dill, W. A., Goulet, J. R., Buchanan, R. A.: Metabolic disposition of diphenylhydantoin in normal human subjects following intravenous administration. Clin. Pharmacol. Ther. 10, 498 (1969).PubMedGoogle Scholar
  18. 18.
    Green, J. R., Friel, P., Amick-Corkill, J. A.: Methods for gas liquid chromatography determinations of carbamazepine, phenytoin, phenobarbitone and primidone. In: Methods of analysis of anti-epileptic drugs (Eds. J. W. A. Meijer, H. Meinardi, C. Gardner- Thorpe, E. van der Kleijn), ICS 286, 176, Amsterdam: Excerpta Medica, New York: American Elsevier Co., Inc. 1973.Google Scholar
  19. 19.
    Guelen, P. J. M., van der Kleijn, E., Woudstra, U.: Statistical evaluation of pharmacokinetic parameters of anti-epileptic drugs. In: Clinical Pharmacology of Anti-Epileptic Drugs (Eds. H. Schneider, D. Janz, C. Gardner-Thorpe, H. Meinardi, A. L. Sherwin), p. 2, Berlin-Heidelberg-New York: Springer 1975.Google Scholar
  20. 20.
    Hansen, J. M., Kristensen, M., Skovsted, L.: Sulthiame (Ospolot), an inhibitor of diphenylhydantoin metabolism. Epilepsia (Amst.) 9, 17 (1968).CrossRefGoogle Scholar
  21. 21.
    Hansen, J. M., Siersback-Nielsen, K., Skovsted, L.: Carbamazepine induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin. Pharmacol. Ther. 12, 539 (1971).PubMedGoogle Scholar
  22. 22.
    Kaplan, S., Jack, S. M. L., Alexander, K., Weinfeld, R.: Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administration. J. Pharm. Sci. 62, 1789 (1973).PubMedCrossRefGoogle Scholar
  23. 23.
    Knop, H., van der Kleijn, E., Edmonds, C. L.: Pharmacokinetics of clonazepam in man and laboratory animals. This volume p. 427.Google Scholar
  24. 24.
    Lindquist, N. G., Ullberg, S.: The melanin affinity of chloroquine and chlorpromazine studied by wholebody autoradiography. Acta Pharmacol. Toxicol. 31, suppl. II (1972).Google Scholar
  25. 25.
    Laubscher, R. A.: Fatal diphenylhydantoin poisoning, a case report. J. Amer. med. Ass. 198, 1120 (1966).CrossRefGoogle Scholar
  26. 26.
    Levy, G., Tsuchiya, T., Amsel, L. P.: Limited capacity for salicylphenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man. Clin. Pharmacol. Ther. 13, 258 (1972).PubMedGoogle Scholar
  27. 27.
    Lundquist, F., Wolthers, H.: The kinetics of alcohol elimination in man. Acta pharmacol. (Kbh.) 14, 265 (1958).CrossRefGoogle Scholar
  28. 28.
    Mannering, G. J.: Biotransformation. In: Antiepileptic Drugs (eds. D. M. Woodbury, J. K. Penry, R. P. Sdimidt), p. 23. New York: Raven Press 1972.Google Scholar
  29. 29.
    Meijer, J. W. A.: Simultaneous quantitative determination of anti-epileptic drugs including carbamazepine, in body fluids. Epilepsia 12, 341 (1971).PubMedCrossRefGoogle Scholar
  30. 30.
    Meijer, J. W. A., Meinardi, H., Gardner-Thorpe, C., van der Kleijn, E., editors: Methods of analysis of anti-epileptic drugs. ICS 286, Amsterdam: Excerpta Medica 1973.Google Scholar
  31. 31.
    Meilink, J. H.: Fluorimetric assay of carbamazepine and its metabolites in blood. Pharm. Weekbl. 109, 22 (1974).Google Scholar
  32. 32.
    Meinardi, H.: Carbamazepine. In: Anti-epileptic Drugs (Eds. D. M. Woodbury, J. K. Penry, R. P. Schmidt) 487. New York: Raven Press 1973.Google Scholar
  33. 33.
    Morselli, P. L., Biandrate, P., Frigerio, A., Gerna, M., Tognoni, G.: Gas chromatographic determination of carbamazepine and carbamazepine-10,ll-epoxide in human body fluids. Methods of Analysis of Anti-epileptic Drugs (J. W. A. Meijer, H. Meinardi, C. Gardner- Thorpe, E. van der Kleijn), ICS 286, 169. Amsterdam: Excerpta Medica, New York: American Elsevier Co., Inc. 1973.Google Scholar
  34. 34.
    Morselli, P. L., Rizzo, M., Garattini, S.: Interactions between phenobarbital and diphenylhydantoin in animals and in epileptic patients. Ann. N. Y. Acad. Sci. 179, 88 (1971).PubMedCrossRefGoogle Scholar
  35. 35.
    Nakamura, K., Masuda, Y., Nakatsuji, K., Hiroka, T.: Comparative studies on the distribution and metabolic fate of diphenylhydantoin and 3-ethylcarbomyldiphenylhydantoin after chronic administration to dogs and cats. Naunyn Schmiedebergs Arch. Pharmacol. 254, 406 (1966).Google Scholar
  36. 36.
    Palmer, L., Bertilsson, L., Collste, P., Rawlins, M.: Quantitative determination of Carbamazepin in plasma by mass fragmentography. Clin. Pharmacol. 14, 827 (1973).Google Scholar
  37. 37.
    Schobben, F., van der Kleijn, E.: Determination of sodium di-n-propylacetate in plasma by gas-liquid chromatography. Pharm. Weekbl. 109, 1 (1974).Google Scholar
  38. 38.
    Schobben, F., van der Kleijn, E.: Pharmacokinetics of distribution and elimination of sodium di-n-propylacetate in mouse and dog. Pharm. Weekbl. 109, 33 (1974).Google Scholar
  39. 39.
    Schobben, F., Gabreels, A., van der Kleijn, E.: Pharmacokinetics of di-n-propylacetate in epileptic patients. Europ. J. clin. Pharmacol. 8, 97–105 (1975).CrossRefGoogle Scholar
  40. 40.
    Sherwin, A. L.: Anticonvulsant drugs in human epileptogenic brain. Arch. Neurol. 29, 73 (1973).PubMedCrossRefGoogle Scholar
  41. 41.
    Shirkey, H. C.: Pediatric Dosage Handbook. Amer. Pharm. Ass. 1973.Google Scholar
  42. 42.
    Sjöqvist, F., Alexanderson, B.: Drug interactions: a critical look at their documentation and clinical importance. Excerpta med. Internat. Congr. Scr. 254, 167 (1972).Google Scholar
  43. 43.
    Solomon, H. M., Schrogie, J. J.: The effect of phenyramidol on the metabolism of diphenylhydantoin. Clin. Pharmacol. Ther. 8, 554 (1967).PubMedGoogle Scholar
  44. 44.
    Suzuki, T., Saitoh, J., Nishihara, K.: Kinetics of diphenylhydantoin disposition in man. Chem. Pharm. Bull. 18, 405 (1970).PubMedCrossRefGoogle Scholar
  45. 45.
    Tigelaar, R. E., Rapport, R. L., Inman, J. K., Kupferberg, H. J.: A radio-immuno assay for diphenylhydantoin. Clin. Chim. Acta 43, 231 (1973).PubMedCrossRefGoogle Scholar
  46. 46.
    Tyrer, J. H., Eadie, M. J., Sutherland, J. M., Hooper, W. D.: Outbreak of anticonvulsant intoxication in an Australian city. Brit. Med. J. 1970 IV, 271.CrossRefGoogle Scholar
  47. 47.
    van der Kleijn, E.: Kinetics of general and regional brain distribution of closely related 7-chloro-l,4-benzodiazepines. Benzodiazepines, p. 145. New York: Raven Press 1973.Google Scholar
  48. 48.
    van der Kleijn, E., Collste, P., Norlander, B., Agurell, S., Sjöqvist, F.: Gas chromatographic determination of ethosuximide and phensuximide in plasma and urine of man. J. Pharm. Pharmacol. 25, 324 (1973).PubMedCrossRefGoogle Scholar
  49. 49.
    van der Kleijn, E., Pijnappel, H., van Wijk, C., Guelen, P., Rijntjes, N.: Pharmacokinetic concepts for chronic treatment with anti-epileptic drugs. In: Methods of Analysis of anti-epileptic drugs. (Eds. J. W. A. Meijer, H. Meinardi, C. Gardner-Thorpe, E. van der Kleijn), ICS 286, 9, Amsterdam: Excerpta Medica 1973.Google Scholar
  50. 50.
    van der Pol, W. S., Deeleman, R., van der Kleijn, E., Lauw, M., Schönefeld, H., van Rossum, J. M., Crul, J. F.: Linear and non-linear pharmacokinetics of 4-hydroxybutyrate in humans. J. Pharmacokinetics and Biopharmaceutics, submitted for publication.Google Scholar
  51. 51.
    van Ginneken, C. A. M., van Rossum, J. M., Fleuren, H. L. J. M.: Linear and non-linear kinetics of drug elimination. J. Pharmacokinetics and Biopharmaceutics, Vol. II, 5, 395 to 415 (1974).CrossRefGoogle Scholar
  52. 52.
    Vree, T. B., Henderson, P. Th., van Rossum, J. M., Doukas, P. H.: In vivo and in vitro inhibition of the metabolism of N-alkyl substituted amphetamines in rat by ferrocenylisopropylamine. Xenobiotica 3, 23 (1973).PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin-Heidelberg 1975

Authors and Affiliations

  • E. van der Kleijn
    • 1
  • P. J. M. Guelen
    • 1
  • C. van Wijk
    • 1
  • I. Baars
    • 1
  1. 1.Department of Clinical Pharmacy, Sint Radboud HospitalUniversity of NijmegenNijmegenThe Netherlands

Personalised recommendations